Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

67.97 +2.69 (+4.12%)
Streaming Delayed Price Updated: 12:07 PM EST, Jan 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
7 Biotech Stocks to Buy as Sector Rotation Ramps Up ↗
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation. 
Via InvestorPlace
News headline image
The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024 ↗
The Russell 2000 is up about 4% year to date, and could push higher, taking the most undervalued Russell 2000 stocks along for the ride. 
Via InvestorPlace
News headline image
Cracking The Code: Understanding Analyst Reviews For Arrowhead Pharma ↗
 
Via Benzinga
News headline image
Recap: Arrowhead Pharma Q1 Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 6, 2024 ↗
Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion. 
Via Benzinga
News headline image
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday ↗
U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday. 
Via Benzinga
Topics Stocks
News headline image
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. 
Via Benzinga
Topics Stocks
News headline image
7 Oversold Russell 2000 Stocks to Add to Your February Buy List ↗
Investors may want to jump into oversold Russell 2000 stocks. After a rough outing in 2023, many are starting to come back strong. 
Via InvestorPlace
News headline image
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On. ↗
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy. 
Via Investor's Business Daily
News headline image
7 Biotech Stocks Fighting America’s Deadliest Diseases ↗
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
4 Analysts Assess Arrowhead Pharma: What You Need To Know ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Arrowhead Pharma ↗
 
Via Benzinga
News headline image
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
News headline image
Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Lamb Weston Holdings, Inc. (NYSE: LW) rose during Thursday’s session following... 
Via Benzinga
Topics Stocks
News headline image
Why SoFi Technologies Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) fell sharply during Wednesday’s session after Keefe, Bruyette & Woods downgraded rating on the stock. 
Via Benzinga
News headline image
Why Arrowhead Pharmaceuticals Shares Are Moving ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) shares are trading higher by 5.4% to $32.68, gaining after initially falling, after the company priced an underwritten registered offering of about 15.79... 
Via Benzinga
News headline image
TDCX Receives Preliminary Non-binding Proposal Letter, Joins Pure Storage, Dyne Therapeutics And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks traded lower, with the Nasdaq Composite falling around 150 points on Wednesday. Shares of TDCX Inc. (NYSE: TDCX) rose sharply during Wednesday’s session after it disclosed receiving a... 
Via Benzinga
Topics Stocks
News headline image
Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback ↗
Piper Sandler sees potential turnaround for Biotech sector in 2024, identifies thee top stocks; Arrowhead, Legend Biotech & Alnylam Pharmaceuticals. 
Via Benzinga
News headline image
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.